公开(公告)号：US20230273218A1

公开(公告)日：2023-08-31

申请号：US18027240

申请日：2021-06-10

Applicant: HANGZHOU ZHEDA DIXUN BIOLOGICAL GENE ENGINEERING CO., LTD.

Inventor： Zhoujie WU ,  Yi LIU ,  Shandong WU ,  Huahao SHEN ,  Shanshan CHEN ,  Shaochang WU ,  Yifei WANG ,  Mingzhi ZHU ,  Meijie WANG ,  Chuhan CHEN

IPC: G01N33/68 ,  G01N33/545 ,  G01N33/577 ,  G01N33/58

CPC classification number: G01N33/6854 ,  G01N33/545 ,  G01N33/577 ,  G01N33/582 ,  G01N33/6869 ,  G01N33/6866 ,  G01N2800/60

Abstract: The present disclosure relates to a kit for quantitative detection using a fluorescent microarray, and belongs to the technical field of protein detection. The kit of the present disclosure includes a detection plate and a detection antibody coupled with fluorescent microspheres, where the detection plate is provided with a plurality of reaction chambers; the reaction chamber is provided with an opening, and an inner bottom surface of the reaction chamber is provided with a plurality of detection sites that are arranged side by side along a length direction of the reaction chamber at an interval. The kit of the present disclosure may detect allergen-specific IgE, IgG and IgA with high sensitivity, as well as rapidly and quantitatively detect an allergen-specific antibody IgE, IgG and IgA concentration in human serum or plasma, and may screen dozens of allergens at a time.

公开(公告)号：US11739141B2

公开(公告)日：2023-08-29

申请号：US16807902

申请日：2020-03-03

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young Seong ,  Jong Ik Hwang ,  Woong Sun ,  Eun Bee Cho ,  Won-Ki Kim

IPC: C07K16/24 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/577 ,  G01N33/68 ,  A61K39/00 ,  C07K14/47 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

CPC classification number: C07K16/24 ,  A61K38/1709 ,  A61K48/00 ,  C07K14/4701 ,  C07K14/4702 ,  C07K16/18 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/577 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/141 ,  C12Q2600/156 ,  G01N2333/47

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

公开(公告)号：US11725046B2

公开(公告)日：2023-08-15

申请号：US16958213

申请日：2018-12-28

Applicant: ZHUHAI TRINOMAB BIOTECHNOLOGY CO., LTD.

Inventor： Huaxin Liao ,  Yueming Wang ,  Xiaohui Yuan ,  Weihong Zheng

IPC: C07K16/12 ,  G01N33/569 ,  G01N33/577

CPC classification number: C07K16/1282 ,  G01N33/56911 ,  G01N33/577 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/33

Abstract: The invention describes fully native human neutralizing monoclonal antibodies against tetanus toxin. The invention developed fully native human neutralizing monoclonal antibodies against tetanus toxin through a systematic high through-put platform that is specialized for identifying and developing human native antibody. The neutralizing monoclonal antibodies described in the invention can be used in the prevention, treatment and detection of Clostridium tetani infection. The fully human neutralizing monoclonal antibodies developed in the invention have a high affinity toward tetanus toxin, as well as possessing high neutralizing activities against the toxin, safe of use with high disease prevention effectiveness, free of exogenous virus contamination, and are widely applicable to various human groups with strong industrial applications.

公开(公告)号：US11673969B2

公开(公告)日：2023-06-13

申请号：US17436744

申请日：2020-09-04

Applicant: HANGZHOU BIOLYNX TECHNOLOGY CO., LTD.

Inventor： Mingzhen Li ,  Li Pan ,  Min Hu ,  Hao Liu

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/44 ,  G01N33/577

CPC classification number: C07K16/44 ,  G01N33/577

Abstract: The present disclosure provides an anti-biotin antibody, and provides an amino acid sequence encoding the CDRs of the antibody. Studies have shown that the antibody only reacts with a biotin conjugate or derivative, and does not react with free biotin. The present disclosure further provides applications of the antibody in, including but not limited to, ELISA, cell capture, sorting and enrichment, western blotting, flow cytometry, immunocytofluorescent staining, and immunohistochemistry. The anti-biotin antibody conjugated immunomagnetic beads can specifically and directly recognize a biotin labeled antigen, and do not bind to free biotin which is often presented in clinical samples and culture media. In addition, the anti-biotin antibody-conjugated magnetic beads or anti-biotin antibody-fluorescein provide an ideal solution for the isolation of specific cells, and can even enrich and separate target cells from samples rich in debris or other rare biological materials.

公开(公告)号：US20230174647A1

公开(公告)日：2023-06-08

申请号：US17845742

申请日：2022-06-21

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Diana Yuhui Chen ,  Andrew Rankin ,  Xiaodi Deng ,  Joseph Toth ,  Linda Liang ,  Michelle Minhua Han ,  Christine Bee ,  Hong-An Truong ,  Mark J. Selby ,  Nils Lonberg ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Alan J. Korman

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/563 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/563 ,  G01N33/577 ,  A61K2039/505

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

公开(公告)号：US11667710B2

公开(公告)日：2023-06-06

申请号：US17016744

申请日：2020-09-10

Applicant: Alector LLC

Inventor： Arnon Rosenthal ,  Kate Monroe ,  Seung-Joo Lee

IPC: C07K16/28 ,  G01N33/577 ,  G01N33/574 ,  A61P31/04 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61P25/00 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/574 ,  G01N33/577

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230160901A1

公开(公告)日：2023-05-25

申请号：US17532871

申请日：2021-11-22

Applicant: Universiti Brunei Darussalam

Inventor： Minhaz Uddin AHMED ,  Juthi ADHIKARI ,  Mohammad RIZWAN

IPC: G01N33/577 ,  G01N21/66 ,  G01N33/58

CPC classification number: G01N33/577 ,  G01N21/66 ,  G01N33/583 ,  B82Y30/00

Abstract: The present application discloses an electrochemiluminescence (ECL) immunosensor. The ECL immunosensor includes an electrode modified by a nanocomposite comprising a mixture of carbon nanochips (CNCs); iron oxide (Fe3O4); and nafion (NAF). The electrode is a screen-printed electrode which further is a carbon screen-printed electrode (SPE). The carbon screen-printed electrode (SPE) is a mesoporous carbon screen-printed electrode (SPE). Ru(bpy)3Cl2.6H2O is a luminophore and TPrA is a coreactant of the luminophore.

公开(公告)号：US20230145894A1

公开(公告)日：2023-05-11

申请号：US17996861

申请日：2021-04-26

Applicant: INSTITUT PASTEUR

Inventor： Thierry Rose ,  Sophie GOYARD ,  Laurent Lionel REBER ,  Yves JANIN

IPC: C07K16/42 ,  C12N9/02 ,  G01N33/535 ,  G01N33/533 ,  G01N33/577

CPC classification number: C07K16/4291 ,  C12N9/0069 ,  G01N33/535 ,  G01N33/533 ,  G01N33/577 ,  C07K2317/22 ,  C07K2317/622

Abstract: The present invention relates to a fusion protein comprising: —a N-terminal domain which comprises an antibody which is a variable domain of a camelid heavy-chain antibody (VHH) or a single chain variable fragment (scFV) and which is directed against an immunoglobulin and —a C-terminal domain which comprises a polypeptide with a luciferase activity: —having the amino acid sequence SEQ ID NO: 1 or —having at least 80% amino acid sequence identity to the amino acid sequence SEQ ID NO: 1.

公开(公告)号：US20230138647A1

公开(公告)日：2023-05-04

申请号：US17913575

申请日：2021-03-25

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Joshua Fuqua ,  Krystal Hamorsky ,  Kenneth Palmer ,  Jill M. Steinbach-Rankins

IPC: G01N33/543 ,  G01N33/569 ,  G01N33/577

Abstract: A lateral flow assay and compositions for performing such an assay are described herein that detect whole virus (e.g., HIV, HCV, HSV-2) or viral proteins that use the broad-spectrum anti-viral lectin, griffisthin (GRFT), conjugated to polymeric or gold nanoparticles (NPs) and an appropriate monoclonal antibody (mAb) to confer virus selectivity.

公开(公告)号：US20230073067A1

公开(公告)日：2023-03-09

申请号：US17763621

申请日：2021-02-23

Applicant: Institute of Microbiology, Chinese Academy of Science

Inventor： Jinghua YAN ,  Rui SHI ,  Qihui WANG ,  Fu GAO ,  Sufang MA

IPC: C07K16/10 ,  G01N33/577 ,  G01N33/569 ,  A61P31/14

Abstract: Provided in the present invention are a humanized monoclonal antibody for the 2019 novel coronavirus (2019-nCOV) and the use thereof. The antibody is capable of specifically binding with a receptor binding domain (RBD) of 2019-nCOV and blocking the binding between the RBD of 2019-nCOV and ACE2, and furthermore inhibiting the infection caused by 2019-nCOV.